NAMS - NewAmsterdam Pharma Company NV Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Current Price & Safety Score Price: 21.07 USD StockBonds Safety Grade: D Altman Z-Score (Bankruptcy Risk): 18.31 StockBond Score: -2.63 Company Description NewAmsterdam Pharma Company NV a latestage biopharmaceutical company develops therapies to enhance patient care in populations with cardiometabolic disease It is developing Obicetrapib an oral lowdose cholesteryl ester transfer protein CETP inhibitor that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDLC for cardiovascular diseases The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimers disease NewAmsterdam Pharma Company NV is headquartered in Naarden the Netherlands